DeepMed Research

Conbercept

Generic Name: Conbercept

Drug Type: Biotech

CAS Number: 1227158-72-6

Unique Ingredient Identifier: 1P05PW62F3

Background: Conbercept has been investigated for the basic science of Age-related Macular Degeneration.

Indication: 用于治疗湿性年龄相关性黄斑变性(AMD)。

Clinical Trials

Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy

Not Applicable

Recruiting

Conditions: Retinopathy of Prematurity (ROP)

Interventions: Drug: Conbercept

First Posted Date: 2024-12-05

Last Posted Date: 2025-04-04

Lead Sponsor: Wang Yusheng

Target Recruit Count: 146

Registration Number: NCT06717412

Locations: 🇨🇳
Department of Ophthalmology, the Second Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi, China
🇨🇳
Department of Ophthalmology, Xijing Hospital, Air Force Military Medical University, Xi'an, Shaanxi, China
🇨🇳
Department of Ophthalmology, Xianyang Rainbow Hospital, Xianyang, Shaanxi, China

Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy

Phase 4

Recruiting

Conditions: Diabetic Macular Edema

Interventions: Drug: Conbercept

First Posted Date: 2024-03-12

Last Posted Date: 2025-04-24

Lead Sponsor: Shanghai Eye Disease Prevention and Treatment Center

Target Recruit Count: 58

Registration Number: NCT06305143

Locations: 🇨🇳
Shanghai Eye Diseases Prevention &Treatment Center, Shanghai, Shanghai, China

Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Diabetic Macular Edema

Not Applicable

Recruiting

Conditions: Diabetic Macular Edema
Pars Plana Vitrectomy
Conbercept

Interventions: Procedure: Vitrectomy combined with ILM peeling
Drug: Conbercept intravitreal injection

First Posted Date: 2023-02-15

Last Posted Date: 2024-03-06

Lead Sponsor: Tianjin Medical University Eye Hospital

Target Recruit Count: 102

Registration Number: NCT05728476

Locations: 🇨🇳
Tianjin medical university eye hosipital, Tianjin, Tianjin, China

Conbercept for Polypoidal Choroidal Vasculopathy（START Study）

Completed

Conditions: Polypoidal Choroidal Vasculopathy
Conbercept

First Posted Date: 2022-02-08

Last Posted Date: 2022-02-08

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 500

Registration Number: NCT05229237

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China

Anti-VEGF in Real-world

Conditions: Neovascular Age-related Macular Edema
Proliferative Diabetic Retinopathy
Diabetic Macular Edema
Choroidal Neovascular Membrane
Non-proliferative Diabetic Retinopathy
Retinal Vein Occlusion

Interventions: Drug: Ranibizumab
Drug: Aflibercept
Drug: Conbercept

First Posted Date: 2022-02-03

Last Posted Date: 2022-02-03

Lead Sponsor: Wenbin Wei

Target Recruit Count: 1000

Registration Number: NCT05222633

Locations: 🇨🇳
Wen-Bin Wei, Beijing, Beijing, China

A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma

Phase 2

Conditions: Retinoblastoma

Interventions: Drug: Conbercept ophthalmic injection

First Posted Date: 2021-08-04

Last Posted Date: 2021-08-04

Lead Sponsor: Chengdu Kanghong Biotech Co., Ltd.

Target Recruit Count: 92

Registration Number: NCT04990271

Locations: 🇨🇳
The Second Xiangya Hospital Of Central South University, Changsha, Hunan, China
🇨🇳
Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
🇨🇳
Renmin Hospital of Wuhan University, Wuhan, Hubei, China

and more 2 locations

Effects of Adding Triamcinolone Acetonide to Conbercept Treatment for Refractory Diabetic Macular Edema (CONTE)

Not Applicable

Conditions: Diabetes Mellitus, Type 2
Macular Edema

Interventions: Drug: Conbercept and TA
Drug: Conbercept

First Posted Date: 2020-11-13

Last Posted Date: 2020-11-17

Lead Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University

Target Recruit Count: 50

Registration Number: NCT04627402

Locations: 🇨🇳
Zhongshan Opthalmic Center, Guangzhou, Guangdong, China

An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization

Phase 1

Conditions: Corneal Neovascularization

Interventions: Drug: Conbercept eye drop
Drug: Placebo

First Posted Date: 2020-01-02

Last Posted Date: 2020-01-02

Lead Sponsor: Chengdu Kanghong Biotech Co., Ltd.

Target Recruit Count: 39

Registration Number: NCT04215393

Locations: 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
🇨🇳
Renmin Hospital of Wuhan University, Wuhan, Hubei, China

Application of Intravitreal Conbercept Injection as a Primary Treatment for Exudative Circumscribed Choroidal Haemangioma

Early Phase 1

Conditions: Circumscribed Choroidal Haemangioma

Interventions: Drug: conbercept

First Posted Date: 2019-06-04

Last Posted Date: 2019-06-04

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 50

Registration Number: NCT03973125

Locations: 🇨🇳
Kunbei Lai, Guangzhou, Guangdong, China

PRP vs PRP+IVC for Severe nPDR

Not Applicable

Conditions: Severe Nonproliferative Diabetic Retinopathy
Diabete Mellitus
Diabetic Retinopathy

Interventions: Drug: Conbercept
Procedure: Panretinal coagulation

First Posted Date: 2019-03-05

Last Posted Date: 2019-03-05

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 40

Registration Number: NCT03863535

Locations: 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy